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The experience of pain is mediated by a specialized sen-
sory system, the nociceptive system. There is considerable
evidence that the cGMP/cGMP kinase I (cGKI) signaling
pathway modulates the nociceptive processing within the
spinal cord. However, downstream targets of cGKI in this
context have not been identified to date. In this study we
investigated whether cysteine-rich protein 2 (CRP2) is a
downstream effector of cGKI in the spinal cord and is
involved in nociceptive processing. Immunohistochemis-
try of the mouse spinal cord revealed that CRP2 is
expressed in superficial laminae of the dorsal horn. CRP2
is colocalized with cGKI and with markers of primary
afferent C fibers. Importantly, the majority of CRP2
mRNA-positive dorsal root ganglion (DRG) neurons
express cGKI and CRP2 is phosphorylated in a cGMP-
dependent manner. To elucidate the functional role of
CRP2 in nociception, we investigated the nociceptive
behavior of CRP2-deficient (CRP2-/-) mice. Touch percep-
tion and acute thermal nociception were unaltered in
CRP2-/- mice. However, CRP2-/- mice showed an increased
nociceptive behavior in models of persistent pain as com-
pared to wild type mice. Intrathecal administration of
cGKI activating cGMP analogs increased the nociceptive
behavior in wild type but not in CRP2-/- mice, indicating
that the presence of CRP2 was essential for cGMP/cGKI-
mediated nociception. These data indicate that CRP2 is a
new downstream effector of cGKI-mediated spinal nocic-
eptive processing and point to an inhibitory role of CRP2
in the generation of inflammatory pain.
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